Please login to the form below

Not currently logged in
Email:
Password:

Digital intelligence blog

Pharma insight on digital marketing, social media, mobile apps, online video, websites and interactive healthcare tools

LEO Pharma invests in skin cancer detection mobile app firm

Willalso collaborate in digital health with Dutch company SkinVision

LEO Pharma

LEO Pharma has invested in SkinVision, whose mobile app of the same name is used to detect skin cancer.

The deal will also see LEO, whose business focuses heavily on skincare products, collaborate with the Dutch digital health company on “global solutions that can expand the reach of SkinVision's technology solutions”.

SkinVision - the app - is already Europe's leading skin cancer detection application and provides consumers with a low-cost and easy-to-use tool for the early detection and evaluation of skin lesions.

Kim Kjoeller, senior VP of global development at LEO Pharma, said: “The internet is dramatically changing how consumers manage their health and that creates new opportunities for us to deliver innovative, value-added services.

“We are very pleased to collaborate with SkinVision, because we will gain unique learnings about the convergence of digital technologies with medical applications.”

He added: “The coming years will see an ever changing and increasingly digital health care environment and LEO Pharma wants to be at the forefront of that trend. This is a huge opportunity for the European technology and pharmaceutical industries to become world leaders.”

LEO said the agreement acknowledged the growing potential of a wide range of digital health technologies “to deliver innovative, consumer centric solutions”.

SkinVision's app currently focuses on lesions, which are identified by taking pictures of moles using a standard smartphone camera and then the images assessed by an algorithm that the company says is over 80% accurate. 

Where the app detects characteristics of unnatural growth, or their potential, the patient is referred to a dermatologist. Users can archive their skin lesions to track for changes over time and share images with their doctor.

A key element of LEO Pharma's investment will see it enable SkinVision to develop its app, which is currently the only skin cancer detection app with European CE certification, into other skin disease areas.

This year has already seen LEO become increasingly active in social media, and in March it set out its social media principles and expanded its presence on Twitter.

8th September 2015

From: Healthcare

Share

Tags

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Attigo (part of the Mednet Group)

We are socially intuitive. Attigo deliver inspiring creative healthcare communications, whilst leading the way as partner of choice for socially-conscious...

Latest intelligence

50 questions for delivering an exceptional healthcare brand experience
Our 50-question brand planning checklist for healthcare ensures you deliver an exceptional experience, based on what your stakeholders want and need...
The brand strategy revolution
Introducing a new tool for developing a stakeholder-centric brand, based on the experience your patients and their HCPs want and need....
How Medisafe is using AI to improve patient adherence
Dina Patel speaks to Omri Shor, Co-Founder and CEO of Medisafe, to find out how his medication management app is tackling the problem of poor adherence....

Infographics